多灶性肝细胞癌的异质性免疫基因组特征与不同免疫逃逸机制
该研究对15例多灶性肝细胞癌患者的47个肿瘤进行全外显子/转录组测序、多重免疫染色、免疫肽组、TCR测序及生物信息分析,揭示肝内转移与多中心发生具有不同的克隆结构、突变谱和免疫微环境时空异质性,免疫编辑主要见于多中心发生,HLA杂合性缺失见于17%的多灶性肝癌并损害新抗原呈递,整合免疫评分、免疫编辑、TCR克隆性和HLA杂合性缺失可分层复发风险(p=0.038)。
要点
- 肝内转移与多中心发生的克隆结构、突变谱和免疫微环境存在显著差异
- HLA杂合性缺失见于17%的多灶性肝癌,尤其损害肝内转移的新抗原呈递
- 整合免疫评分、免疫编辑、TCR克隆性和HLA杂合性缺失可分层复发风险(p=0.038)
核心结论
- 多灶性肝细胞癌的遗传结构、新表位景观、T细胞特征和免疫编辑状态共同塑造肿瘤进化,可用于优化个体化免疫治疗。
研究设计与样本
- 对15例多灶性肝细胞癌患者的47个肿瘤联合全外显子/转录组测序、多重免疫染色、免疫肽组、TCR测序和生物信息分析。
主要发现
- 肝内转移和多中心发生具有不同的克隆结构、突变谱和遗传易感性。
- 免疫微环境呈时空异质性,肝内转移T细胞浸润较少、M2巨噬细胞较多,多中心发生抑制性免疫检查点表达较高。
- 同一患者肿瘤间共享新抗原和TCR库在肝内转移中丰富、在多中心发生中稀少。
- 免疫编辑主要发生于多中心发生而非肝内转移,与免疫浸润相对较低有关。
- HLA等位基因杂合性缺失见于17%的多灶性肝癌,损害MHC呈递新抗原的能力,尤其在肝内转移中。
关键数值与推荐
- 整合免疫评分、免疫编辑、TCR克隆性和HLA杂合性缺失可将患者分为高或低复发风险两组(p = 0.038)。
- 结合新抗原预测和免疫肽组可鉴定T细胞特异性新表位,并在体外获得高验证率。
临床怎么用
- 对多灶性肝细胞癌应认识肝内转移与多中心发生的免疫基因组差异,以指导个体化免疫治疗策略。
- 可整合免疫评分、免疫编辑、TCR克隆性和HLA杂合性缺失评估复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The presence of multifocal tumors, developed either from intrahepatic metastasis (IM) or multicentric occurrence (MO), is a distinct feature of hepatocellular carcinoma (HCC). Immunogenomic characterization of multifocal HCC is important for understanding immune escape in different lesions and developing immunotherapy. METHODS: We combined whole-exome/transcriptome sequencing, multiplex immunostaining, immunopeptidomes, T cell receptor (TCR) sequencing and bioinformatic analyses of 47 tumors from 15 patients with HCC and multifocal lesions. RESULTS: IM and MO demonstrated distinct clonal architecture, mutational spectrum and genetic susceptibility. The immune microenvironment also displayed spatiotemporal heterogeneity, such as less T cell and more M2 macrophage infiltration in IM and higher expression of inhibitory immune checkpoints in MO. Similar to mutational profiles, shared neoantigens and TCR repertoires among tumors from the same patients were abundant in IM but scarce in MO. Combining neoantigen prediction and immunopeptidomes identified T cell-specific neoepitopes and achieved a high verification rate in vitro. Immunoediting mainly occurred in MO but not IM, due to the relatively low immune infiltration. Loss of heterozygosity of human leukocyte antigen (HLA) alleles, identified in 17% of multifocal HCC, hampered the ability of major histocompatibility complex to present neoantigens, especially in IM. An integrated analysis of Immunoscore, immunoediting, TCR clonality and HLA loss of heterozygosity in each tumor could stratify patients into 2 groups based on whether they have a high or low risk of recurrence (p = 0.038). CONCLUSION: Our study comprehensively characterized the genetic structure, neoepitope landscape, T cell profile and immunoediting status that collectively shape tumor evolution and could be used to optimize personalized immunotherapies for multifocal HCC. LAY SUMMARY: Immunogenomic features of multifocal hepatocellular carcinoma (HCC) are important for understanding immune-escape mechanisms and developing more effective immunotherapy. Herein, comprehensive immunogenomic characterization showed that diverse genomic structures within multifocal HCC would leave footprints on the immune landscape. Only a few tumors were under the control of immunosurveillance, while others evaded the immune system through multiple mechanisms that led to poor prognosis. Our study revealed heterogeneous immunogenomic landscapes and immune-constrained tumor evolution, the understanding of which could be used to optimize personalized immunotherapies for multifocal HCC.
引用
- Dong LQ, Peng LH, Ma LJ, et al. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma. J Hepatol. 2019. PMID: 31887370. doi:10.1016/j.jhep.2019.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。